From Glioblastoma Treatments
Jump to navigationJump to search
Property Information
Drug Name MN-166 (Ibudilast)
FDA Approval Approved in Japan for post-stroke complications and bronchial asthma; in late-stage clinical development for ALS, Progressive MS, DCM in other regions
Used for Experimental for ALS, Progressive MS, DCM, glioblastoma, CIPN, Long COVID, and substance use disorder
Clinical Trial Phase Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder
Clinical Trial Explanation Not specified
Common Side Effects Not specified; has been used in Japan with a good post-marketing safety profile
OS without Not specified
OS with Not specified
PFS without Not specified
PFS with Not specified
Usefulness Rating 3 (awaiting research)
Usefulness Explanation Not specified
Toxicity Level 1
Toxicity Explanation MN-166 (Ibudilast) is generally regarded as having a low toxicity level due to its long-term use in Japan for other conditions. On a scale of 1 to 5, with 5 being the most toxic, it is rated at 1. This means that the drug is generally well-tolerated and the risk of severe side effects is relatively low. However, as MN-166 (Ibudilast) is still undergoing clinical trials for glioblastoma and other conditions outside of Japan, it's vital to consult closely with a healthcare provider before considering this treatment option.

Notes: MN-166 (Ibudilast) is a small molecule compound that inhibits PDE4 and inflammatory cytokines including MIF. It is being developed by MediciNova for a broad range of conditions, including neurodegenerative diseases and glioblastoma, and has been in use in Japan for over 20 years. The drug is in various stages of clinical development in other regions, including Phase 3 for ALS and DCM, and Phase 2 for glioblastoma and substance use disorder.


From Ben Williams Book: Not specified

Loading comments...